Nonopioid Lofexidine Safe and Effective for Managing Opioid Withdrawal Syndrome
Lofexidine may expand the treatment options available for managing withdrawal when buprenorphine and methadone are unavailable or undesirable.
Lofexidine may expand the treatment options available for managing withdrawal when buprenorphine and methadone are unavailable or undesirable.
Borderline personality disorder, a disorder that is often misunderstood by the general public, also raises questions for psychiatrists.
At 6 weeks of treatment, severely ill patients treated with adjunctive brexpiprazole had a greater reduction in PANSS total scores and CGI-S scores compared with those receiving placebo.
This research provides further support to compelling data linking inflammation and depression.
The researchers believe this study is the first to detect a statistically significant, unexpected inverse association between efavirenz use and depression.
The researchers found significant advantages from dialectical behavior therapy in all primary outcomes.
The Janssen Pharmaceutical Companies of Johnson & Johnson have announced the results of 2 long-term phase 3 clinical trials examining esketamine nasal spray in patients with treatment-resistant depression.
Widespread use of antidepressants may be contributing to long-term increased risk for weight gain.
Dr Stewart has held executive leadership positions in public behavioral health systems in Michigan, New York, and Pennsylvania. Her career has spanned 3 decades in public sector administration.
This study had a sample size large enough to assess the effect of circadian disruption on mental health disorders, and was the first to objectively measure patterns of rest and activity (using accelerometers).